Seminars in Oncology
Volume 31, Issue 5 , Pages 618-634, October 2004

Anaplastic astrocytoma: Diagnosis, prognosis, and management

  • Siew Ju See

      Affiliations

    • Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore.
  • ,
  • Mark R. Gilbert

      Affiliations

    • Department of Neuro-oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
    • Corresponding Author InformationAddress reprint requests to Mark R. Gilbert, MD, Department of Neuro-oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

The designation of a tumor as anaplastic astrocytoma (AA) reflects a distinct histologic classification of malignant glioma characterized by an abundance of pleomorphic astrocytes with evidence of mitosis. Although these tumors are malignant, they have a better prognosis and a higher likelihood of response to treatment than glioblastoma. Despite advances in brain tumor imaging, making an accurate diagnosis requires the evaluation of tumor tissue and is essential for treatment planning. Currently, most patients undergo maximal surgical debulking of tumor followed by external beam radiation, often with subsequent adjuvant chemotherapy. However, despite the use of these treatment modalities, most tumors recur within a few years and these recurrent tumors are more refractory to subsequent therapies. This review examines the diagnosis, prognosis, and treatment of AAs. Ongoing clinical research investigations are also summarized, reflecting advances in our knowledge of the molecular pathogenesis of these tumors and providing hope for significant improvements in patient outcomes.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(04)00326-4

doi:10.1053/j.seminoncol.2004.07.004

Seminars in Oncology
Volume 31, Issue 5 , Pages 618-634, October 2004